Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review

Abstract

Patients with locally advanced cervical cancer (LACC) treated with chemoradiation often experience hematologic toxicity (HT), as chemoradiation can induce bone marrow (BM) suppression. Studies on the relationship between BM dosimetric parameters and clinically significant HT might provide relevant indices for developing BM sparing (BMS) radiotherapy techniques. This systematic review studied the relationship between BM dose and HT in patients with LACC treated with primary cisplatin-based chemoradiation. A systematic search was conducted in Embase, Medline, and Web of Science. Eligibility criteria were treatment of LACC-patients with cisplatin-based chemoradiation and report of HT or complete blood cell count (CBC). The search identified 1346 papers, which were screened on title and abstract before two reviewers independently evaluated the full-text. 17 articles were included and scored according to a selection of the TRIPOD criteria. The mean TRIPOD score was 12.1 out of 29. Fourteen studies defining BM as the whole pelvic bone contour (PB) detected significant associations with V10 (3/14), V20 (6/14), and V40 (4/11). Recommended cut-off values were V10 > 95-75%, V20 > 80-65%, and V40 > 37-28%. The studies using lower density marrow spaces (PBM) or active bone marrow (ABM) as a proxy for BM only found limited associations with HT. Our study was the first literature review providing an overview of articles evaluating the correlation between BM and HT for patients with LACC undergoing cisplatin-based chemoradiation. There is a scarcity of studies independently validating developed prediction models between BM dose and HT. Future studies may use PB contouring to develop normal tissue complication probability models.

Keywords: Bone marrow; Chemoradiotherapy; Dose-response relationship; Hematologic toxicity; Proton therapy; Radiation; Uterine cervical neoplasms.

Conflict of interest statement

Conflicts of interest Erasmus MC Radiotherapy has research agreements with Accuray and Elekta. NH reports to have received research grants from the Dutch Cancer Society and Varian. MH reports to have received research grants from Varian Medical Systems and clinical advisory membership of Accuracy. RN reports to have received research grants outside the submitted work from Dutch Cancer Society, Dutch Research Council, Elekta, Varian Medical Systems, and Accuracy. The other authors have declared no conflicts of interest.

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.